Další formáty:
BibTeX
LaTeX
RIS
@article{1355420,
author = {Pospíšilová, Šárka and Sutton, LesleyandAnn and Malčíková, Jitka and Tausch, Eugen and Rossi, Davide and Montserrat, Emili and Moreno, Carol and Stamatopoulos, Kostas and Gaidano, Gianluca and Rosenquist, Richard and Ghia, Paolo},
article_location = {PAVIA},
article_number = {3},
doi = {http://dx.doi.org/10.3324/haematol.2015.139246},
keywords = {CLONAL EVOLUTION; MUTATIONS; SURVIVAL; TRIAL; PROGRESSION; IMPACT; CLL},
language = {eng},
issn = {0390-6078},
journal = {Haematologica},
title = {Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?},
url = {http://www.haematologica.org/content/101/3/263.full.pdf+html},
volume = {101},
year = {2016}
}
TY - JOUR
ID - 1355420
AU - Pospíšilová, Šárka - Sutton, Lesley-Ann - Malčíková, Jitka - Tausch, Eugen - Rossi, Davide - Montserrat, Emili - Moreno, Carol - Stamatopoulos, Kostas - Gaidano, Gianluca - Rosenquist, Richard - Ghia, Paolo
PY - 2016
TI - Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
JF - Haematologica
VL - 101
IS - 3
SP - 263-265
EP - 263-265
PB - FERRATA STORTI FOUNDATION
SN - 03906078
KW - CLONAL EVOLUTION
KW - MUTATIONS
KW - SURVIVAL
KW - TRIAL
KW - PROGRESSION
KW - IMPACT
KW - CLL
UR - http://www.haematologica.org/content/101/3/263.full.pdf+html
L2 - http://www.haematologica.org/content/101/3/263.full.pdf+html
N2 - T he prognostication of patients with chronic lympho- cytic leukemia (CLL) currently relies on both clinical and biological parameters (Figure 1). The prime exam- ple concerns the TP53 gene, whereby inactivation of TP53 , resulting from either a mutation or chromosome 17p deletion, is associated with a short time to progression, an early need for treatment, and an overall dismal outcome. 1,2 The presence of TP53 aberrations is also a strong predictor of treatment response, as patients carrying such lesions respond poorly to standard chemoimmunotherapy (CIT) (i.e. fludarabine, cyclophosphamide, and rituximab). 3 Although TP53 abnor- malities are infrequent at diagnosis (5%-10%), they are found in 40%-50% of advanced or therapy-refractory cases, hence underscoring the need to re-assess TP53 gene status as the dis- ease progresses and clones evolve.
ER -
POSPÍŠILOVÁ, Šárka, Lesley-Ann SUTTON, Jitka MALČÍKOVÁ, Eugen TAUSCH, Davide ROSSI, Emili MONTSERRAT, Carol MORENO, Kostas STAMATOPOULOS, Gianluca GAIDANO, Richard ROSENQUIST a Paolo GHIA. Innovation In the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go? \textit{Haematologica}. PAVIA: FERRATA STORTI FOUNDATION, 2016, roč.~101, č.~3, s.~263-265. ISSN~0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2015.139246.
|
